Last reviewed · How we verify

Levamlodipine besylate — Competitive Intelligence Brief

Levamlodipine besylate (Levamlodipine besylate) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Dihydropyridine calcium channel blocker. Area: Cardiovascular.

marketed Dihydropyridine calcium channel blocker L-type voltage-gated calcium channel Cardiovascular Small molecule Live · refreshed every 30 min

Target snapshot

Levamlodipine besylate (Levamlodipine besylate) — Jiangsu Simcere Pharmaceutical Co., Ltd.. Levamlodipine besylate is the active L-enantiomer of amlodipine that blocks L-type calcium channels in vascular smooth muscle and cardiac tissue, causing vasodilation and reducing blood pressure.

Comparator set (6 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

DrugGenericSponsorPhaseClassTargetApproval / PDUFA
Levamlodipine besylate TARGET Levamlodipine besylate Jiangsu Simcere Pharmaceutical Co., Ltd. marketed Dihydropyridine calcium channel blocker L-type voltage-gated calcium channel
trandolapril/verapamil trandolapril/verapamil Abbott marketed ACE inhibitor / calcium channel blocker combination Angiotensin-converting enzyme (ACE); L-type voltage-gated calcium channels
Lacidipine & Amlodipine Lacidipine & Amlodipine Korea University Guro Hospital marketed Dihydropyridine calcium channel blocker L-type voltage-gated calcium channel
Amlodipine + Indapamide Amlodipine + Indapamide Centre for Chronic Disease Control, India marketed Calcium channel blocker + Thiazide-like diuretic combination L-type voltage-gated calcium channels (amlodipine); sodium-chloride cotransporter (indapamide)
nifedipine CR tablets (Adalat) nifedipine CR tablets (Adalat) Shanghai Shyndec Pharmaceutical Co., Ltd. marketed Calcium channel blocker (dihydropyridine) L-type voltage-gated calcium channel
nicardipine intravenous nicardipine intravenous Haseki Training and Research Hospital marketed Dihydropyridine calcium channel blocker L-type voltage-gated calcium channel
Amlodipine+Benazepril Amlodipine+Benazepril TSH Biopharm Corporation Limited marketed Calcium channel blocker + ACE inhibitor combination L-type voltage-gated calcium channels; Angiotensin-converting enzyme (ACE)

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Dihydropyridine calcium channel blocker class)

  1. Bayer · 1 drug in this class
  2. CSPC Zhongnuo Pharmaceutical (Shijiazhuang) Co., Ltd. · 1 drug in this class
  3. Haseki Training and Research Hospital · 1 drug in this class
  4. Jiangsu Simcere Pharmaceutical Co., Ltd. · 1 drug in this class
  5. Korea University Guro Hospital · 1 drug in this class
  6. Nanjing Yoko Biomedical Co., Ltd. · 1 drug in this class
  7. Organon and Co · 1 drug in this class
  8. Pfizer Inc. · 1 drug in this class
  9. University Hospital Hradec Kralove · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Levamlodipine besylate — Competitive Intelligence Brief. https://druglandscape.com/ci/levamlodipine-besylate. Accessed 2026-05-16.

Build your own brief

Pick any drug + add comparators: